Skip to content
Head to head

PTC Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: PTCT · VRTX

Updated 10 minutes ago

1-year performance, rebased to 100

PTCT -25.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
PTCTVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price56.42515.02
Change today-3.27%-1.08%
1-year return-26.2%+22.0%
Market cap$4.71B$130.58B
52-week range56.18 – 90.87412.27 – 568.67
Valuation
P/E (TTM)-42.4233.14
P/E percentile, own 5-yr range6th99th
P/B-24.656.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)7.7815.32
Net profit (TTM)$649.97M$3.88B
Revenue (TTM)$1.16B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+69.6%+11.8%
Gross margin93.2%85.5%
Operating margin12.0%33.1%
Net margin-9.2%30.7%
Free cash flow (TTM)$-41.32M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership124.9%96.8%
Insider activity (12mo)7 buy / 40 sell28 buy / 22 sell
Short interest (% of float)9.3%1.9%
Analyst consensus83% buy / 17% hold (12)95% buy / 5% hold (21)
Analyst price target$100 (+77%)$624 (+21%)
StockVane view
StockVane Quant RatingD (17)C (68)
Company
Employees1,0476,400
Founded19981989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.